{"id":913984,"date":"2025-11-26T07:36:05","date_gmt":"2025-11-26T12:36:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/"},"modified":"2025-11-26T07:36:05","modified_gmt":"2025-11-26T12:36:05","slug":"silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/","title":{"rendered":"Silexion Therapeutics to Present at Noble Capital Markets&#8217; 21st Annual Emerging Growth Equity Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>Grand Cayman, Cayman Islands, Nov.  26, 2025  (GLOBE NEWSWIRE) &#8212; Silexion Therapeutics Corp. (\u201cSilexion\u201d or the \u201cCompany\u201d), a clinical-stage, oncology-focused biotechnology company, today announced that Company management will be attending and presenting at the Noble Capital Markets&#8217; 21<sup>st<\/sup> Annual Emerging Growth Equity Conference (NobleCon21).<\/p>\n<p>\n        <u>Presentation details:<br \/><\/u><br \/>\n        <strong>Type:<\/strong> Company presentation<br \/><strong>Date:<\/strong> December 3, 2025<br \/><strong>Time:<\/strong> 2:30 \u2013 2:55pm ET<br \/><strong>Speakers<\/strong>: Ilan Hadar, Chief Executive Officer and Mirit Horenshtein-Hadar, Chief Financial Officer<br \/><strong>Location<\/strong>: Florida Atlantic University Conference Center, Boca Raton, FL, Presentation Room 5.<\/p>\n<p>Silexion\u2019s management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.<\/p>\n<p>Following the conference, a replay of the presentation will be posted to SIlexion\u2019s investor relations website\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xPtIgeabIV5HGtPpw1Y5_StwXj6mUQWTBVb6CQdPBVbHUQD-ncdy2PJffknUSs5h0ClynA2GQfVyY3q6kfe1J1EsIIUd_zmIkBGi8TRB5JF0q88hR7JFyqnwh5yWeL7H\" rel=\"nofollow\" target=\"_blank\">events and presentations<\/a> page available using the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FVZUcrKqzgQ4mcj4U0CvVluYVL8mpoq0wBOfGEmuvhFGQ2Qv6m08mwgFALLGL9pkgVEuEevnTsv_aVDIMzsj7KG30kLkKrXsS1dLBWZvjfMch77YhIH7B56zWseE3myljIjHejkl7XO4u1msUeUKeg==\" rel=\"nofollow\" target=\"_blank\">https:\/\/silexion.com\/presentations\/<\/a><\/p>\n<p>\n        <strong><br \/>\n          <br \/>About Silexion Therapeutics<br \/><\/strong>Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https:\/\/silexion.com<\/p>\n<p>\n        <strong>Company Contact:<br \/><\/strong>Silexion Therapeutics Corp<br \/>Ms. Mirit Horenshtein Hadar, CFO<br \/>mirit@silexion.com<\/p>\n<p>\n        <strong>Investor Contacts:<br \/><\/strong>Arx Investor Relations<br \/>North American Equities Desk<br \/>silexion@arxhq.com<\/p>\n<p>Chuck Padala\u202f<br \/>LifeSci Advisors\u202f<br \/>Chuck@lifesciadvisors.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0MTA0MiM0MDIyNzE2MTQjMjI5NjY3Mg==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/OWFkNTExMjUtN2UyYy00NmM1LWE5MjctMGI3Zjc2NGZjYTRmLTEzMDgyMjItMjAyNS0xMS0yNi1lbg==\/tiny\/Silexion-Therapeutics-Corp.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) &#8212; Silexion Therapeutics Corp. (\u201cSilexion\u201d or the \u201cCompany\u201d), a clinical-stage, oncology-focused biotechnology company, today announced that Company management will be attending and presenting at the Noble Capital Markets&#8217; 21st Annual Emerging Growth Equity Conference (NobleCon21). Presentation details: Type: Company presentationDate: December 3, 2025Time: 2:30 \u2013 2:55pm ETSpeakers: Ilan Hadar, Chief Executive Officer and Mirit Horenshtein-Hadar, Chief Financial OfficerLocation: Florida Atlantic University Conference Center, Boca Raton, FL, Presentation Room 5. Silexion\u2019s management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting. Following the conference, a replay of the presentation will be posted to SIlexion\u2019s investor relations website\u2019s events and presentations page &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silexion Therapeutics to Present at Noble Capital Markets&#8217; 21st Annual Emerging Growth Equity Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-913984","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silexion Therapeutics to Present at Noble Capital Markets&#039; 21st Annual Emerging Growth Equity Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silexion Therapeutics to Present at Noble Capital Markets&#039; 21st Annual Emerging Growth Equity Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) &#8212; Silexion Therapeutics Corp. (\u201cSilexion\u201d or the \u201cCompany\u201d), a clinical-stage, oncology-focused biotechnology company, today announced that Company management will be attending and presenting at the Noble Capital Markets&#8217; 21st Annual Emerging Growth Equity Conference (NobleCon21). Presentation details: Type: Company presentationDate: December 3, 2025Time: 2:30 \u2013 2:55pm ETSpeakers: Ilan Hadar, Chief Executive Officer and Mirit Horenshtein-Hadar, Chief Financial OfficerLocation: Florida Atlantic University Conference Center, Boca Raton, FL, Presentation Room 5. Silexion\u2019s management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting. Following the conference, a replay of the presentation will be posted to SIlexion\u2019s investor relations website\u2019s events and presentations page &hellip; Continue reading &quot;Silexion Therapeutics to Present at Noble Capital Markets&#8217; 21st Annual Emerging Growth Equity Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-26T12:36:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0MTA0MiM0MDIyNzE2MTQjMjI5NjY3Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silexion Therapeutics to Present at Noble Capital Markets&#8217; 21st Annual Emerging Growth Equity Conference\",\"datePublished\":\"2025-11-26T12:36:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\\\/\"},\"wordCount\":276,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE0MTA0MiM0MDIyNzE2MTQjMjI5NjY3Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\\\/\",\"name\":\"Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE0MTA0MiM0MDIyNzE2MTQjMjI5NjY3Mg==\",\"datePublished\":\"2025-11-26T12:36:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE0MTA0MiM0MDIyNzE2MTQjMjI5NjY3Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE0MTA0MiM0MDIyNzE2MTQjMjI5NjY3Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silexion Therapeutics to Present at Noble Capital Markets&#8217; 21st Annual Emerging Growth Equity Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/","og_locale":"en_US","og_type":"article","og_title":"Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference - Market Newsdesk","og_description":"Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) &#8212; Silexion Therapeutics Corp. (\u201cSilexion\u201d or the \u201cCompany\u201d), a clinical-stage, oncology-focused biotechnology company, today announced that Company management will be attending and presenting at the Noble Capital Markets&#8217; 21st Annual Emerging Growth Equity Conference (NobleCon21). Presentation details: Type: Company presentationDate: December 3, 2025Time: 2:30 \u2013 2:55pm ETSpeakers: Ilan Hadar, Chief Executive Officer and Mirit Horenshtein-Hadar, Chief Financial OfficerLocation: Florida Atlantic University Conference Center, Boca Raton, FL, Presentation Room 5. Silexion\u2019s management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting. Following the conference, a replay of the presentation will be posted to SIlexion\u2019s investor relations website\u2019s events and presentations page &hellip; Continue reading \"Silexion Therapeutics to Present at Noble Capital Markets&#8217; 21st Annual Emerging Growth Equity Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-26T12:36:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0MTA0MiM0MDIyNzE2MTQjMjI5NjY3Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silexion Therapeutics to Present at Noble Capital Markets&#8217; 21st Annual Emerging Growth Equity Conference","datePublished":"2025-11-26T12:36:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/"},"wordCount":276,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0MTA0MiM0MDIyNzE2MTQjMjI5NjY3Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/","name":"Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0MTA0MiM0MDIyNzE2MTQjMjI5NjY3Mg==","datePublished":"2025-11-26T12:36:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0MTA0MiM0MDIyNzE2MTQjMjI5NjY3Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0MTA0MiM0MDIyNzE2MTQjMjI5NjY3Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silexion Therapeutics to Present at Noble Capital Markets&#8217; 21st Annual Emerging Growth Equity Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=913984"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913984\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=913984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=913984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=913984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}